NCT07457528 2026-03-11
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
Clinical Trials
73 trialsNCT07205731 2026-03-05
SAFE ESO
University Hospital, Clermont-Ferrand
Phase 2 Recruiting
NCT06452602 2026-02-27
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT07437898 2026-02-27
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
The Affiliated Hospital of Putian University
Phase 2 Recruiting
NCT07385001 2026-02-03
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Tang-Du Hospital
Phase 1/2 Recruiting
NCT05978193 2026-01-22
SCR-ESCC-01
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07359417 2026-01-22
ESCALATE
UMC Utrecht
Phase 1 Recruiting
NCT07317609 2026-01-05
Endosurgery-02
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT07290010 2025-12-17
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT07061704 2025-12-08
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 1/2 Recruiting
NCT07266493 2025-12-05
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06912074 2025-11-17
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07086469 2025-11-17
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07152678 2025-09-03
BRIGHT-ESCC
National Taiwan University Hospital
Phase 2 Recruiting
NCT06509568 2025-08-29
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06596954 2025-08-11
Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase NA Recruiting
NCT06356688 2025-08-08
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07088354 2025-07-28
DL-ESCC
Tongji Hospital
Recruiting
NCT06490003 2025-07-11
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
City of Hope Medical Center
Recruiting
NCT06165380 2025-06-26
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT07016724 2025-06-12
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT06446726 2025-06-06
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2 Recruiting
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06169163 2025-05-02
ViSON
Imperial College London
Recruiting
NCT06637163 2025-04-17
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06907602 2025-04-02
ONTRESCC
Peking Union Medical College Hospital
Phase 2/3 Recruiting
NCT05028725 2025-03-30
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma
University of California, San Francisco
Phase NA Recruiting
NCT06885814 2025-03-20
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04460352 2025-03-06
NEEDS
Karolinska University Hospital
Phase 3 Recruiting
NCT06654297 2024-12-11
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT06603402 2024-12-03
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
Sichuan University
Phase 2 Recruiting
NCT06329869 2024-12-02
SG-ESCC
National Taiwan University Hospital
Phase 2 Recruiting
NCT06709417 2024-11-29
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06710665 2024-11-29
Tumor Regression Grade As Predictor of Adjuvant Therapy
Fujian Medical University Union Hospital
Recruiting
NCT06690476 2024-11-15
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
Peking University
Phase EARLY_PHASE1 Recruiting
NCT06684600 2024-11-12
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Recruiting
NCT06675201 2024-11-05
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2 Recruiting
NCT06663059 2024-10-29
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Tang-Du Hospital
Phase 2 Recruiting
NCT06510660 2024-09-19
RICE
Fujian Medical University Union Hospital
Phase 2 Recruiting
NCT06561178 2024-08-29
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
Sun Yat-sen University
Recruiting
NCT06563869 2024-08-21
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT06498752 2024-08-06
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06138028 2024-07-24
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Qingdao Central Hospital
Phase 2/3 Recruiting
NCT06354140 2024-07-17
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT05490719 2024-05-21
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting